tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

PHVS Stock Latest News

Pharvaris Secures Registration Rights Agreement with General Atlantic
Company AnnouncementsPharvaris Secures Registration Rights Agreement with General Atlantic
15d ago
6K
PHVS
Pharvaris Advances Clinical Pipeline with Strong Financials
PremiumCompany Announcements
Pharvaris Advances Clinical Pipeline with Strong Financials
1M ago
PHVS
Pharvaris’ Strategic Advancements and Financial Strength Bolster Buy Rating
PremiumRatings
Pharvaris’ Strategic Advancements and Financial Strength Bolster Buy Rating
1M ago
PHVS
Pharvaris: Buy Rating Backed by Promising Trial Milestones and Strong Financial Position
PremiumRatings
Pharvaris: Buy Rating Backed by Promising Trial Milestones and Strong Financial Position
1M ago
PHVS
Pharvaris price target lowered to $52 from $55 at Citizens JMP
PremiumThe Fly
Pharvaris price target lowered to $52 from $55 at Citizens JMP
1M ago
PHVS
Pharvaris Reports Q2 2025 Financials and Advances Phase 3 Studies
PremiumCompany AnnouncementsPharvaris Reports Q2 2025 Financials and Advances Phase 3 Studies
1M ago
6K
PHVS
Pharvaris Raises $201 Million in Successful Offering
Premium
Company Announcements
Pharvaris Raises $201 Million in Successful Offering
2M ago
6K
PHVS
Pharvaris 8.25M share Spot Secondary priced at $20.00
Premium
The Fly
Pharvaris 8.25M share Spot Secondary priced at $20.00
2M ago
PHVS
Pharvaris announces $150M ordinary shares offering
PremiumThe Fly
Pharvaris announces $150M ordinary shares offering
2M ago
PHVS
Pharvaris’s Accelerated Phase 3 Trial Timeline and Market Potential Boost Buy Rating
PremiumRatings
Pharvaris’s Accelerated Phase 3 Trial Timeline and Market Potential Boost Buy Rating
2M ago
PHVS
Pharvaris’s Promising Outlook: Accelerated Timeline and Market Potential for Deucrictibant in HAE Treatment
PremiumRatings
Pharvaris’s Promising Outlook: Accelerated Timeline and Market Potential for Deucrictibant in HAE Treatment
2M ago
PHVS
Pharvaris Updates RAPIDe-3 Study Timeline for HAE Treatment
PremiumCompany Announcements
Pharvaris Updates RAPIDe-3 Study Timeline for HAE Treatment
3M ago
6K
PHVS
Pharvaris to report topline Phase 3 results of deucrictibant in Q4
PremiumThe FlyPharvaris to report topline Phase 3 results of deucrictibant in Q4
3M ago
PHVS
Pharvaris Announces Key Resolutions from Annual General Meeting
Premium
Company Announcements
Pharvaris Announces Key Resolutions from Annual General Meeting
3M ago
6K
PHVS
Pharvaris initiated with a Buy at Guggenheim on HAE potential
Premium
The Fly
Pharvaris initiated with a Buy at Guggenheim on HAE potential
3M ago
PHVS
Pharvaris initiated with a Buy at Guggenheim
PremiumThe Fly
Pharvaris initiated with a Buy at Guggenheim
3M ago
PHVS
Pharvaris Announces 2025 Annual Shareholders Meeting Amidst Phase 3 Trials
PremiumCompany Announcements
Pharvaris Announces 2025 Annual Shareholders Meeting Amidst Phase 3 Trials
4M ago
6K
PHVS
Pharvaris’s Deucrictibant: Expanding Market Reach in Bradykinin-Mediated Angioedemas with Promising Phase 3 Trials
PremiumRatings
Pharvaris’s Deucrictibant: Expanding Market Reach in Bradykinin-Mediated Angioedemas with Promising Phase 3 Trials
4M ago
PHVS
Pharvaris’s Strategic Advancements and Clinical Progress Justify Buy Rating
PremiumRatings
Pharvaris’s Strategic Advancements and Clinical Progress Justify Buy Rating
4M ago
PHVS
Pharvaris presents data supporting ongoing clinical development of deucrictibant
PremiumThe FlyPharvaris presents data supporting ongoing clinical development of deucrictibant
4M ago
PHVS
Pharvaris: Strong Buy Rating Backed by Clinical Progress and Financial Stability
Premium
Ratings
Pharvaris: Strong Buy Rating Backed by Clinical Progress and Financial Stability
4M ago
PHVS
Pharvaris’s Promising Pipeline Progress and Strong Financial Position Justify Buy Rating with $43 Target
Premium
Ratings
Pharvaris’s Promising Pipeline Progress and Strong Financial Position Justify Buy Rating with $43 Target
4M ago
PHVS

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >